di(2H-imidazol-2-yl)methanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: di(2H-imidazol-2-yl)methanone
• 英文别名: 1,1'-carbonyldiimidazole；1,1-carbonyldiimidazole；carbonyldiimidazole；cabonyldiimidazole；di(1H-imidazol-1-yl)methanone；CDI；bis(2H-imidazol-2-yl)methanone
• 化学式: C₇H₆N₄O
• 分子量: 162.151
• InChiKey: AYQAXMOGKIFXOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  66.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,5,6-三甲基-2-羧酸 、 di(2H-imidazol-2-yl)methanone 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (1H-imidazol-1-yl)(3,5,6-trimethylpyrazin-2-yl)methanone
  参考文献：
  名称：

  Ligustrazine Derivatives. Part 6: Design, Synthesis and Evaluation of Novel Ligustrazinyl Acylguanidine Derivatives as Potential Cardiovascular Agents

  摘要：

  A series of novel Ligustrazinyl acylguanidines was designed, synthesized and evaluated for their protective effect on injured vascular endothelial cell (ECV-304). The preliminary results demonstrated that some compounds possessed more potent activities than that of Ligustrazine in stimulating replication of the injured endothelial cell. Among the active compounds, compounds 8b, 8f and 8l displayed remarkable antioxidative activity with low EC50 values of 0.097, 0.059 and 0.094 mM, respectively. Structure-activity relationships were briefly discussed.

  DOI：

  10.2174/157340612802084243
• 作为试剂：
  描述：

  2-氨基-4-溴吡啶 、 BOC-甘氨酸 在 di(2H-imidazol-2-yl)methanone 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 以59%的产率得到tert-butyl (2-((5-bromopyridin-2-yl)amino)-2-oxoethyl)carbamate
  参考文献：
  名称：

  Vemurafenib靶向MKK4的新型荧光标记类似物的设计与合成

  摘要：

  有丝分裂原活化的蛋白激酶激酶4（MKK4）在肝脏再生中起关键作用，并且正在作为刺激肝细胞增加增殖的靶标进行研究。因此，新的抑制MKK4的小分子可能代表治疗急性和慢性肝病的有前途的方法。荧光标记的化合物是用于大型化合物库的高通量筛选的有用工具。在这里，我们利用了FDA批准的BRAF抑制剂vemurafenib 1的基于氮杂吲哚的支架，该支架对MKK4表现出脱靶活性，以此作为我们荧光化合物设计的起点。支架的化学变化和优化导致选择了在MKK4上具有高结合亲和力的荧光5-TAMRA衍生物。化合物45 代表一种合适的工具化合物，用于荧光偏振测定法以鉴定新的MKK4小分子抑制剂。

  DOI：

  10.1016/j.ejmech.2020.112901

文献信息

• Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activation
  作者：Yanhui Yang、Andrew Voak、Shane R. Wilkinson、Longqin Hu

  DOI：10.1016/j.bmcl.2012.09.005

  日期：2012.11

  A series of potential DFMO prodrugs was designed through the incorporation of 4-nitrobenzyl ester or carbamate groups for potential activation by trypanosomal nitroreductase. It was found that only modification of Nε-amino group of DFMO by 4-nitro-2-fluorobenzyloxycarbonyl resulted in significant trypanocidal activity and could serve as a lead for further investigation.

  通过并入4-硝基苄基酯或氨基甲酸酯基团，设计了一系列潜在的DFMO前药，以通过锥虫硝基还原酶进行潜在的激活。结果发现，仅修改Ñ ε氨基DFMO的由4-硝基-2- fluorobenzyloxycarbonyl导致显著杀锥虫活性，可作为供进一步调查的引线。
• [EN] NOVEL ANTIVIRAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTIVIRAUX
  申请人：PHARMARESOURCES SHANGHAI CO LTD

  公开号：WO2012065062A1

  公开（公告）日：2012-05-18

  The present invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection such as HIV using the same.

  本发明涉及一种化合物I的化学式：或其药用可接受的盐，其中符号如规范中定义；包括相同化合物的药物组合物，以及使用该化合物治疗或预防病毒感染，如HIV的方法。
• [EN] BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDÈNE-AMINE À SUBSTITUTION BIPHÉNYLE
  申请人：NOVARTIS AG

  公开号：WO2011157787A1

  公开（公告）日：2011-12-22

  The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of one or more IGF-1 R mediated disorders or diseases.

  这项发明涉及公式（I）的新衍生物，其中取代基如规范中所定义；制备这种衍生物的方法；包括这种衍生物的药物组合物；将这种衍生物用作药物；将这种衍生物用于治疗一个或多个IGF-1 R介导的疾病。
• AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS
  申请人：Hoffmann-La Roche Inc

  公开号：US20130090334A1

  公开（公告）日：2013-04-11

  Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

  公式(I)的化合物： 或其药用可接受的盐，其中R1和R2如本文所述定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与钙释放激活钙通道（CRAC）相关疾病的用途。
• Urea and thiourea compounds and compositions for cholesterol management and related uses
  申请人：Dasseux Henri Jean-Louis

  公开号：US20050192347A1

  公开（公告）日：2005-09-01

  The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, enhancing bile production, enhancing reverse lipid transport, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, modulating C reactive protein, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), a thrombotic disorder, gastrointestinal disease, irritable bowel syndrome (IBS), inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), arthritis (e.g., rheumatoid arthritis, osteoarthritis), autoimmune disease (e.g., systemic lupus erythematosus), scleroderma, ankylosing spondylitis, gout and pseudogout, muscle pain: polymyositis/polymyalgia rheumatica/fibrositis; infection and arthritis, juvenile rheumatoid arthritis, tendonitis, bursitis and other soft tissue rheumatism. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新型尿素和硫脲化合物，包含尿素或硫脲化合物的组合物，以及用于治疗和预防衰老、阿尔茨海默病、癌症、心血管疾病、糖尿病肾病、糖尿病视网膜病变、葡萄糖代谢紊乱、血脂异常、脂蛋白异常、增强胆汁产生、增强逆向脂质转运、高血压、阳痿、炎症、胰岛素抵抗、胆汁中脂质的清除、调节C反应蛋白、肥胖、胆汁中氧固醇的清除、胰腺炎、帕金森病、过氧化物酶体增殖激活受体相关的疾病、胆汁中磷脂的清除、肾脏疾病、败血症、代谢综合征疾病（如X综合症）、血栓性疾病、胃肠道疾病、肠易激综合症（IBS）、炎症性肠病（如克罗恩病、溃疡性结肠炎）、关节炎（如类风湿性关节炎、骨关节炎）、自身免疫疾病（如系统性红斑狼疮）、硬皮病、强直性脊柱炎、痛风和假性痛风、肌肉疼痛：多发性肌炎/多发性肌痛症/纤维炎；感染和关节炎、儿童类风湿性关节炎、肌腱炎、滑囊炎和其他软组织风湿病的方法。在某些实施方式中，本发明的化合物、组合物和方法可与其他治疗药物（如降胆固醇和降血糖药物）联合治疗。